Format

Send to

Choose Destination
Interv Cardiol Clin. 2017 Jan;6(1):141-149. doi: 10.1016/j.iccl.2016.08.010.

Genetic Determinants of P2Y12 Inhibitors and Clinical Implications.

Author information

1
Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, University of Florida, 1333 Center Drive, PO Box 100486, Gainesville, FL 32610, USA. Electronic address: lcavallari@cop.ufl.edu.
2
Division of General Internal Medicine, Department of Medicine, The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, USA; Department of Pharmacy, The Mount Sinai Hospital, New York, NY, USA.

Abstract

There is significant interpatient variability in clopidogrel effectiveness, which is due in part to cytochrome P450 (CYP) 2C19 genotype. Approximately 30% of individuals carry CYP2C19 loss-of-function alleles, which have been consistently shown to reduce clopidogrel effectiveness after an acute coronary syndrome and percutaneous coronary intervention. Guidelines recommend consideration of prasugrel or ticagrelor in these patients. A clinical trial examining outcomes with CYP2C19 genotype-guided antiplatelet therapy is ongoing. In the meantime, based on the evidence available to date, several institutions have started clinically implementing CYP2C19 genotyping to assist with antiplatelet selection after percutaneous coronary intervention.

KEYWORDS:

CYP2C19; Clopidogrel; Genotype; Pharmacogenomics; Prasugrel; Ticagrelor

PMID:
27886818
PMCID:
PMC5134418
DOI:
10.1016/j.iccl.2016.08.010
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center